DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Bioequivalence Study of Anastrozole 1 mg Tablet

Information source: Asan Medical Center
ClinicalTrials.gov processed this data on August 20, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Healthy

Intervention: CJ anastrozole 1 mg tablet (Drug)

Phase: N/A

Status: Completed

Sponsored by: Asan Medical Center

Official(s) and/or principal investigator(s):
Hyeong-Seok Lim, MD, Principal Investigator, Affiliation: Asan Medical Center

Summary

The purpose of this study is to characterize and compare the bioequivalence of CJ anastrozole [CJ Cheiljedang corp., Seoul, Korea] with Arimidex® [AstraZeneca, Wilmington, DE, USA].

Clinical Details

Official title: Bioequivalence Study of CJ Anastrozole 1mg Tablet and Arimidex® 1 mg Tablet

Study design: Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment

Detailed description: This study was conducted to characterize and compare the pharmacokinetic and safety profiles and the bioequivalence of a newly developed new generation aromatase inhibitor (CJ anastrozole) with existing anastrozole formulation (Arimidex®) in healthy Korean volunteers. This study is designed as single-dose, randomized, double-blind, 2-way crossover trial. Participants were randomized to receive 1 mg of either the CJ anastrozole or Arimidex, followed by a 3-week washout period. And then the alternate formulation was administered. After 10-hour overnight fast drug was administered. For analysis of pharmacokinetic properties, including Cmax and AUClast, blood samples were obtained at 0. 33, 0. 67, 1, 1. 5, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 168, and 216 hours after drug administration.

Eligibility

Minimum age: 19 Years. Maximum age: 55 Years. Gender(s): Male.

Criteria:

Inclusion Criteria:

- Healthy male volunteers in the age between 19 to 55 years old

- Subjects were neither congenital nor chronic diseases.

- Subjects were selected after passing a clinical screening procedure that included a

physical examination and laboratory tests.

- Availability of subject for the entire study period and willingness to adhere to

protocol requirements, as evidenced by a signed Informed Consent Form. Exclusion Criteria:

- Any history of a clinical condition which might affect drug absorption, distribution,

metabolism or excretion or might be risk factors, e. g. clinically significant disorder in heart, liver, respiratory system, liver, kidney, gastrointestinal system and CNS

- Had a history of myocardial infarction, stroke, hypertension, arrhythmia, coronary

artery disease, disease of neuropsychiatry, gastrointestinal system surgery (excluding appendectomy, herniotomy)

- Current clinically significant disorder in history taking or physical examination

- Acute disease within 14 days preceding the first application of study medication

- Had an relevant allergic disease

- Had history of hypersensitivity to drugs or any food

- Positive for Hepatitis B antigen, Hepatitis C antibody, HIV antibody, or High Quality

Syphilis Reagin Test

- Excessive caffeine, alcohol intake and smoker(caffeine>5 units/day, alcohol>3

units/day(1 unit = pure alcohol 10ml), cigarettes> 20 cigarettes /day)

- Subjects who excessive alcohol intake or drug which affect drug metabolism enzyme

intake within 30 days preceding study

- History of drug abuse or positive for urinary testing of drugs abuse (amphetamine,

barbiturates, cocaine, opioids, benzodiazepines etc.)

- Has donated whole blood within 60days or apheresis within 14days preceding the first

application of study medication

- Received other investigational drug within 60days preceding the first application of

study medication

- Taken any herbal medicine within 30days, prescription medication within 14 days or

over-the-counter drug (except for vitamins, minerals) within 10days preceding the first application of study medication (might affect this study or safety of subjects as judged by the investigator)

- Subjects could not eat ASAN MEDICAL CENTER standard meal or were unsuitable for this

study as judged by investigators

Locations and Contacts

Additional Information

U.S. FDA Resources

Starting date: June 2008
Last updated: April 15, 2010

Page last updated: August 20, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017